Amgen Inc. (AMGN)
| Market Cap | 152.09B |
| Revenue (ttm) | 34.92B |
| Net Income (ttm) | 6.62B |
| Shares Out | 538.36M |
| EPS (ttm) | 12.23 |
| PE Ratio | 23.10 |
| Forward PE | 13.60 |
| Dividend | $9.52 (3.37%) |
| Ex-Dividend Date | Aug 22, 2025 |
| Volume | 864,259 |
| Open | 279.80 |
| Previous Close | 280.10 |
| Day's Range | 279.00 - 285.29 |
| 52-Week Range | 253.30 - 339.17 |
| Beta | 0.48 |
| Analysts | Hold |
| Price Target | 320.11 (+13.31%) |
| Earnings Date | Oct 29, 2025 |
About AMGN
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company’s principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet’s disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascul... [Read more]
Financial Performance
In 2024, Amgen's revenue was $33.42 billion, an increase of 18.57% compared to the previous year's $28.19 billion. Earnings were $4.09 billion, a decrease of -39.11%.
Financial StatementsAnalyst Summary
According to 19 analysts, the average rating for AMGN stock is "Hold." The 12-month stock price target is $320.11, which is an increase of 13.31% from the latest price.
News
AMGEN TO PRESENT AT THE MORGAN STANLEY 23RD ANNUAL GLOBAL HEALTHCARE CONFERENCE
THOUSAND OAKS, Calif. , Sept. 4, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the Morgan Stanley 23rd Annual Global Healthcare Conference at 9:15 a.m.
Global drugmakers rush to boost US presence as tariff threat looms
Global drugmakers are scrambling to shore up their U.S. manufacturing capacity and domestic inventory as the Trump administration weighs hefty tariffs on pharmaceutical imports into the country.
Amgen Inc. (AMGN) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 Transcript
Amgen Inc. (NASDAQ:AMGN) Wells Fargo 20th Annual Healthcare Conference 2025 September 3, 2025 10:15 AM EDT Company Participants Adam Elinoff Paul Burton - Senior VP & Chief Medical Officer Casey Capp...
AMGEN INVESTING MORE THAN HALF A BILLION DOLLARS IN NEW, STATE-OF-THE-ART CENTER FOR SCIENCE AND INNOVATION AT U.S. GLOBAL HEADQUARTERS
Research and Development Infrastructure Investment Expected to Create Hundreds of U.S. Jobs THOUSAND OAKS, Calif. , Sept. 2, 2025 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced plans to invest...
Amgen to invest $600 million in new research and development facility in California
Amgen said it will spend more than $600 million to build a new research and development facility at its headquarters in Thousand Oaks, California. It is the latest in a string of new U.S. investments ...
AMGEN TO PRESENT AT THE 2025 WELLS FARGO HEALTHCARE CONFERENCE
THOUSAND OAKS, Calif. , Aug. 29, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the 2025 Wells Fargo Healthcare Conference at 10:15 a.m.
Calls of the Day: Micron, DoorDash, Amer Sports, Amgen, Merck and Costco
The Investment Committee debate the latest Calls of the Day.
REPATHA® NOW INDICATED FOR ADULTS AT INCREASED RISK FOR MAJOR ADVERSE CARDIOVASCULAR EVENTS DUE TO UNCONTROLLED LDL-C
THOUSAND OAKS, Calif. , Aug. 25, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has broadened the approved use of Repatha® (evolocumab) to in...
Royalty Pharma to buy royalty interest in Amgen's lung cancer drug for up to $950 million
Royalty Pharma said on Monday it has signed a deal with BeOne Medicines to acquire a royalty interest in Amgen's drug for small cell lung cancer for up to $950 million.
Back To Basics: Why I Favor Amgen Over Johnson & Johnson
Both Amgen (AMGN) and Johnson & Johnson (JNJ) recently received a 60-day ultimatum to lower their prices in the U.S. market. A fundamental analysis shows AMGN to be better positioned than JNJ to absor...
August Dogs Of The Dow Unleashed 19 'Safer' Dividend Buys
Verizon is the only Dow stock currently meeting the 'dogcatcher' ideal: annual dividends from $1K invested exceed its share price and are supported by free cash flow. Analyst forecasts suggest top Dow...
Amgen Stock Sinks As Market Eyes MariTide's Next Move
Amgen Inc. AMGN shares are trading lower on Wednesday, despite the company reporting second-quarter results that surpassed analyst expectations after markets closed on Tuesday.
Why I Still Don't Think Amgen Is A Buy
Amgen delivered strong Q2 2025 results, beating expectations and raising full-year guidance, driven by robust growth in key products despite Enbrel's decline. MariTide, Amgen's promising obesity/diabe...
Amgen Inc. (AMGN) Q2 2025 Earnings Call Transcript
Amgen Inc. (NASDAQ:AMGN) Q2 2025 Earnings Conference Call August 5, 2025 4:30 PM ET Company Participants & - Corporate Participant James E. Bradner - Executive Vice President of Research Development ...
Amgen beats on Q2 revenue, slightly raises guidance
CNBC's Angelica Peebles joins 'Closing Bell: Overtime' to discuss Amgen's Q2 earnings results.
Amgen quarterly results beat Wall Street estimates
Amgen on Tuesday posted quarterly financial results that beat Wall Street expectations as a 9% increase in product sales offset higher operating expenses.
AMGEN REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS
THOUSAND OAKS, Calif. , Aug. 5, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced financial results for the second quarter of 2025.
3 Dividend Stocks for August 2025
These three dividend payers have an average yield of 4.5%.
Former Amgen SVP of Global Research and Renowned Cell Biologist Ray Deshaies Named to Iambic's Scientific Advisory Board
SAN DIEGO--(BUSINESS WIRE)--Iambic Therapeutics, a clinical-stage life science and technology company developing novel medicines using its AI-driven discovery and development platform, today announced...
Buy or Sell Amgen Stock Ahead of Its Earnings?
Amgen (NASDAQ:AMGN) is set to release its earnings on Tuesday, August 5, 2025. Historically, Amgen's stock has shown a tendency to experience negative one-day returns following its earnings announceme...
AMGEN ANNOUNCES 2025 THIRD QUARTER DIVIDEND
THOUSAND OAKS, Calif. , Aug. 1, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $2.38 per share dividend for the third quarter of 2025.
Pharmaceutical makers were largely unshaken by new demands from President Trump to lower drug prices, with experts saying the measures would either have modes impact or face legal challenges
Measures laid out in letters to 17 companies would either have modest impact or face legal challenges, say industry experts.
Pres. Trump's push to lower drug prices 'is a good starting point', says Dr. Scott Gottlieb
Former FDA Commissioner Dr. Scott Gottlieb joins 'Squawk Box' to discuss news of President Trump ordering pharma companies to lower U.S. drug prices in the next 60 days, the move to tiered pricing glo...
President Trump demands drugmakers slash prices within 60 days
CNBC's Joe Kernen reports on the latest news.
AMGEN ANNOUNCES WEBCAST OF 2025 SECOND QUARTER FINANCIAL RESULTS
THOUSAND OAKS, Calif. , July 31, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it will report its second quarter 2025 financial results on Tuesday, August 5, 2025, after the close of t...